The Antidiabetic Drug Liraglutide Minimizes the Non-Cholinergic Neurotoxicity of the Pesticide Mipafox in SH-SY5Y Cells
- 115 Downloads
Organophosphorus (OPs) compounds have been widely used in agriculture, industry, and household, and the neurotoxicity induced by them is still a cause of concern. The main toxic mechanism of OPs is the inhibition of acetylcholinesterase (AChE); however, the delayed neuropathy induced by OPs (OPIDN) is mediated by other mechanisms such as the irreversible inhibition of 70% of NTE activity (neuropathy target esterase) that leads to axonal degeneration. Liraglutide is a long-lasting GLP-1 analog clinically used as antidiabetic. Its neurotrophic and neuroprotective effects have been demonstrated in vitro and in experimental models of neurodegenerative diseases. As in OPIDN, axonal degeneration also plays a role in neurodegenerative diseases. Therefore, this study investigated the protective potential of liraglutide against the neurotoxicity of OPs by using mipafox as a neuropathic agent (at a concentration able to inhibit and age 70% of NTE activity) and a neuronal model with SH-SY5Y neuroblastoma cells, which express both esterases. Liraglutide protected cells against the neurotoxicity of mipafox by increasing neuritogenesis, the uptake of glucose, the levels of cytoskeleton proteins, and synaptic-plasticity modulators, besides decreasing the pro-inflammatory cytokine interleukin 1β and caspase-3 activity. This is the first study to suggest that liraglutide might induce beneficial effects against the delayed, non-cholinergic neurotoxicity of OPs.
KeywordsLiraglutide Mipafox Organophosphate-induced delayed neuropathy (OPIDN) Neuroplasticity Neuroprotection
This study received financial support from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Grants 307657/2016-7 and 140105/2015-8) and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, Grants 2012/00168-6, 2012/16319-3 and 2013/26906-6).
Compliance with Ethical Standards
Conflict of Interest Statement
The authors declare that they have no conflicts of interest.
- Benomar Y, Naour N, Aubourg A, Bailleux V, Gertler A, Djiane J, Guerre-Millo ML, Taouis M (2006) Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase- dependent mechanism. Endocrinology 147:2550–2556CrossRefGoogle Scholar
- Caudle WM (2015) Chapter 14 - Occupational exposures and parkinsonism. In: Lotti M, Bleecker ML (eds) Handbook of clinical neurology. ElsevierGoogle Scholar
- Ehrich M, Jortner BS (2001) Organophosphate-induced delayed neuropathy. In: Massaro EJ (ed) Handbook of Neurotoxicology. Humana Press Inc., TotowaGoogle Scholar
- Gill KD, Flora G, Pachauri V, Flora SJS (2010) Neurotoxicity of organophosphates and carbamates. In: Satoh T, Gupta RC (eds) Anticholinesterase pesticides. Metabolism, neurotoxicity, and epidemiology. Wiley, New JerseyGoogle Scholar
- Husain K (2014) Delayed neurotoxicity of organophosphorus Compounds. J Environ Immunol Toxicol 1:7Google Scholar
- Johnson MK (1982) The target site for the initiation of delayed neurotoxicity by organophosphorous esters: biochemical studies and toxicological applications. In: Hodgson JR, Philpot RM (eds) Rev Biochem ToxicolGoogle Scholar
- Kevenaar JT, Hoogenraad CC (2015) The axonal cytoskeleton: from organization to function. Front Mol Neurosci 8Google Scholar
- L'episcopo F, Serapide MF, Tirolo C, Testa N, Caniglia S, Morale MC, Pluchino S, Marchetti B (2011) A Wnt1 regulated frizzled-1/beta-catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener 6:49CrossRefGoogle Scholar
- Long-Smith CM, Manning S, McClean PL, Coakley MF, O'Halloran DJ, Holscher C, O'Neill C (2013) The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer’s disease. NeuroMolecular Med 15:102–114CrossRefGoogle Scholar
- Rasband WS 1997-2014. ImageJ, U. S. National Institutes of Health. Bethesda, Maryland, USA http://imagej.nih.gov/ij/
- Richardson RJ, Worden RM, Wijeyesakere SJ, Hein ND, Fink JK, Makhaeva GF (2015) Chapter 63 - Neuropathy target esterase as a biomarker and biosensor of delayed neuropathic agents A2. In: Gupta RC (ed) Handbook of toxicology of chemical warfare agents, 2nd edn. Academic Press, BostonGoogle Scholar
- Schneider L, Giordano S, Zelickson BR, Johnson SM, Bernavides AG, Ouyang X, Fineberg N, Darley-Usmar VM, Zhang J (2011) Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress. Free Radic Biol Med 51:2007–2017CrossRefGoogle Scholar
- Tagliati M (2017) A phase II, randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson’s disease [Online]. https://clinicaltrials.gov/ct2/show/study/NCT02953665
- Vester A, Caudle WM (2016) The synapse as a central target for neurodevelopmental susceptibility to pesticides. Toxics 4Google Scholar
- Voorhees JR, Rohlman DS, Lein PJ, Pieper AA (2017) Neurotoxicity in preclinical models of occupational exposure to organophosphorus compounds. Front Neurosci 10Google Scholar
- Xiong H, Zheng C, Wang J, Song J, Zhao G, Shen H, Deng Y (2013) The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice. J Alzheimers Dis 37:623–635CrossRefGoogle Scholar